Collaborative Advancement of Recovery Excellence
Translating science to service, powered by Gloo
At the National Conference on Addiction Disorders Virtual Experience, Deni Carise, PhD, Chief Scientific Officer at Recovery Centers of America, will discuss services delivery in the time of COVID-19, the intersection of data, outcomes and innovation, and the importance of quality benchmarks and outcomes measurement.
In a study of mice, a synthetic molecule was found to reduce cocaine and methamphetamine consumption and cravings without the side effects typically associated with other interventions, according to research published Thursday in the journal Cell.
Stay-at-home and social-distancing orders have changed how PRSS programs are supporting participants during their most vulnerable moments.
Participants in a South Dakota alcohol-monitoring program that tests frequently for alcohol and swiftly imposes modest penalties for positive or missed tests were found to be less likely to be rearrested on drunk driving charges or have their probation revoked within the following year.
Nearly half of behavioral health executives polled said they see the recovery and wellness of their clients declining in the context of COVID-19, according to the first Weekly Director Poll published by the Psychiatry & Behavioral Health Learning Network and Gloo.
A Johns Hopkins study has found that individuals in recovery who received a supplemental $8 per hour in their wages were more likely to provide drug-free urine samples and maintain steady employment.
In a study of mice, a buprenorphine analog was found to be more effective at activating receptors that prevent cocaine relapse without increasing addiction potential, according to a Science Magazine report.
The Weekly Director Poll, part of the State of the Industry This Week initiative, will provide behavioral healthcare industry executives insights on how their peers are addressing issues of team/staff health, operations, service delivery and more.
A long-term safety study of extended-release buprenorphine illustrates a safety profile comparable to that of the sublingual version of the drug.
A longer duration of treatment with the injectable formulation of buprenorphine for opioid use disorder was associated with more favorable abstinence outcomes in a newly published study.